Angelica has >20 years immune oncology experience (Uppsala University and Baylor College of Medicine). She has a PhD in Medical Sciences from Uppsala University and is currently adjunct as a Professor of immunotherapy. She is an advisor to NEXTTOBE and is a board member of several of their portfolio companies.
Erika been working in the life science sector for >25 years. She has a BSc in Ba and Econ from Uppsala university and started her career as an auditor at Ernst & Young. She is currently the CEO of NEXTTOBE and is a board member of their portfolio companies. Previously, she was vice-president and CFO of Q-Med and a CEO and CFO at Biophausia.
Åsa is specialized in strategic international regulatory affairs and drug development. She has gained more than 30 years of experience in the pharmaceutical industry in projects ranging from first-time-in-man to several products reaching international marketing authorization. Åsa has held leadership positions as Medivir, Orexo, Astra Zeneca R&D, Pharmacia & Upjohn, and Roche AB. Åsa received her MSc in Pharmacy from Uppsala University.
Justyna has a solid background in drug development and the immune-oncology field, and holds a PhD in Medical Sciences from Uppsala University. She has experience as a Sponsor representative for academic and pharma trials. Further, she is a co-founder of the first, successful crowd funding campaign “iCANCER”, held a position of BIO-X project manager and was the Chief Operating Officer of Immuneed.
Sara is an experienced scientist within the academia, and in the health care industry including GE Healthcare (now Cytiva). She holds a Msc in Biotechnology and a PhD in Medical Sciences at Uppsala University, Sweden. She has extensive knowledge and hands-on experience of process development for large-scale production and purification of viral vectors.
Titti holds a Master of Science in Chemistry (Biochemistry) at Uppsala University, Sweden. She has previously worked at Thermo Fisher Scientific and have extended experience of bioreagent manufacturing for medical device including process controls and has solid experience in the quality field and Lean Production.
Linda holds a MSc in Biology and a PhD in Medical Sciences, at Uppsala University, Sweden. She has a strong background in the immune oncology field both from academia, biotech and health care industry including positions at Synovo GmbH in Germany and Astra Zeneca in Cambridge.
Emma holds a Msc in Biomedicine and a PhD in Medical Sciences from Uppsala University, Sweden. She has extensive knowledge and >10 years hands-on experience of genetical engineering, adenovirus manufacture, evaluation of immunotherapies as well as analytical method development.
Malin has more than 20 years of experience within administration and economics in various companies in Sweden, both in life science and government operations, including Q-Med AB, Olink Proteomics AB, and the Swedish Prison and Probation Service.
Eric is an MD whose focus is on the optimal development and registration of anticancer therapeutics. He serves as Executive Director and President of RGenix and CSO of Clearpath Development Co, Board of Biogen Idec. He held many previous positions in both the bioindustry and within academia including Stemline Therapeutics, Primrose Therapeutics, ImClone Systems Inc, Biogen Idec, BIND, Navidea, and Fortress Biosciences.
Mohammad is an MD and holds a PhD in molecular medicine from Uppsala University in Sweden. He is the founder and CEO of a dermatology clinic in Uppsala, the founder of a specialized care center in Gävle and the founder of Aknejouren. Mohammad is a medical consultant to Galderma, CTC Clinical Trial Consultants, LIF Insurance among others. He has extensive experience of clinical trials with focus on protocol design and pharmacovigilance.
Ingrid is an MD, PhD and professor with extensive experience as a senior consultant in Oncology at the Department of Oncology at Uppsala University Hospital. She did her postdoctoral studies at Karolinska Institute within cancer epidemiology and pharmacovigilance. Today she conducts trials both with a clinical, preclinical and epidemiological focus at Uppsala University Hospital/Uppsala University.
Malcolm is an MD, PhD and the Founding Director of the Center for Cell and Gene Therapy at Baylor College of Medicine (BCM), Texas Children's Hospital and Houston Methodist Hospital, Houston, TX. He serves as a Professor in the Departments of Pediatrics and of Medicine at BCM. Brenner received his medical degree and subsequent PhD from the University of Cambridge, England.
Bengt holds a PhD in Physiology from Uppsala University and is the founder of the venture capital company nxt2b. He has held senior positions within Pharmacia and Biomatrix and started the company Q-Med. Q-Med, now Galderma owned, is the world leading company for dermal injectable fillers. Bengt is a former Board Member of the Swedish Foundation for Strategic Research and the former Chairman of Stockholm Uppsala Life Science.
EMA & FDA orphan drug designation: LOAd703 treatment for pancreatic cancer
LOAd703 publication in Clinical Cancer Research
LOKON001: first patient enrolled using LOAd703 + chemotherapy for pancreatic cancer
LOKON002: First patient enrolled using LOAd703 + chemotherapy for selected solid tumors
Patent approved for LOAd703 virus family LOAd713 publication in Journal of Immunology
Roche collaboration - LOKON003: LOAd703 + atezolizumab in melanoma
Roche collaboration - LOKON001 arm 2: LOAd703 + chemo + atezolizumab
LOAd732: data release at AACR
LOKON001: Arm 1 data release at ASCO
LOKON002: biomarker data released at CICON